Who owns Vaxcyte, Inc. (PCVX)? Elite investor 13F holders

4 tracked elite investors reported holding Vaxcyte, Inc as of 2026-09-30, including Caligan Partners, D.E. Shaw, Maverick Capital, Bridgewater Associates. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

4 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent,…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Caligan PartnersVAXCYTE INCSHARE2026-09-302026-11-16 00:00:00124533388.00 USD2188636.000000SharesholdOriginal filing
D.E. ShawVAXCYTE INCSHARE2026-09-302026-11-16 00:00:0081445522.00 USD1431380.000000SharesreduceOriginal filing
Maverick CapitalVAXCYTE INCSHARE2026-09-302026-11-16 00:00:0077385764.00 USD1360031.000000SharesreduceOriginal filing
Bridgewater AssociatesVAXCYTE INCSHARE2026-09-302026-11-16 00:00:002297451.00 USD40377.000000SharesreduceOriginal filing
Renaissance Technologies LLCVAXCYTE INCSHARE2026-09-302026-11-12 00:00:000.00 USD0.000000SharesexitedOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown